Phase I Trial of Ulixertinib (BVD-523) in Combination With Palbociclib in Patients With Advanced Solid Tumors With Expansion Cohort in Previously Treated Metastatic Pancreatic Cancer
Summary
The purpose of this phase I study is to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulixertinib (BVD-523) when combined with the CDK4/6 inhibitor palbociclib.
General Information
NCT#: NCT03454035
Study ID: LCCC1736
Trial Phase: Phase I
Trial Sponsor: Pfizer, BioMed Valley Discoveries, UNC Lineberger Comprehensive Cancer Center
Therapies Used in This Trial: Palbociclib, Ulixertinib